|Bid||2.1300 x 1300|
|Ask||2.1800 x 2200|
|Day's Range||2.0649 - 2.2000|
|52 Week Range||0.6110 - 4.4000|
|Beta (5Y Monthly)||1.13|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 14, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for CNSP
Data presented at the Society of NeuroOncology (SNO) 28th Annual MeetingBerubicin currently being evaluated in an ongoing potentially pivotal study for the treatment of Glioblastoma Multiforme (GBM)Topline result from preplanned interim futility analysis ...
HOUSTON, TX / ACCESSWIRE / November 16, 2023 / Glioblastoma is a highly aggressive type of brain cancer with no cure, leading to a grim prognosis and average survival time of only 14 to 16 months. With no approved treatment for recurrent GBM anywhere ...
- Enrollment numbers rise to 239 in ongoing potentially pivotal study of Berubicin for treatment of GBM; Expected full enrollment in December 2023- Topline data from preplanned interim analysis from ongoing Berubicin potentially pivotal study expected ...